Cargando…

Markers of Oxidative Stress, Inflammation and Endothelial Function following High-Dose Intravenous Iron in Patients with Non-Dialysis-Dependent Chronic Kidney Disease—A Pooled Analysis

Chronic kidney disease (CKD) represents a state of oxidative stress imbalance, which is potentially amplified by iron deficiency. Intravenous iron is considered safe and efficacious in the treatment of iron deficiency anemia, however, concerns remain regarding its potential pro-oxidant effect, leadi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kassianides, Xenophon, White, Steven, Bhandari, Sunil
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9787941/ https://www.ncbi.nlm.nih.gov/pubmed/36555659 http://dx.doi.org/10.3390/ijms232416016

Ejemplares similares

Patient reported outcome measures and cardiovascular outcomes following high dose modern intravenous iron in non-dialysis dependent chronic kidney disease: secondary analysis of ExplorIRON-CKD
por: Kassianides, Xenophon, et al.
Publicado: (2023)

Analysis of oxidative stress, inflammation and endothelial function following intravenous iron in chronic kidney disease in the Iron and Heart Trial
por: Kassianides, Xenophon, et al.
Publicado: (2022)

The comparative effects of intravenous iron on oxidative stress and inflammation in patients with chronic kidney disease and iron deficiency: a randomized controlled pilot study
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Correction to: Protocol and baseline data for a prospective open-label explorative randomized singlecenter comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2020)

The Impact of Intravenous Iron on Renal Injury and Function Markers in Patients With Chronic Kidney Disease and Iron Deficiency Without Anemia
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Hypophosphataemia, fibroblast growth factor 23 and third-generation intravenous iron compounds: a narrative review
por: Kassianides, Xenophon, et al.
Publicado: (2021)

Point-of-care testing technologies for the home in chronic kidney disease: a narrative review
por: Bodington, Richard, et al.
Publicado: (2021)

Safety of intravenous iron use in chronic kidney disease
por: Kalra, Philip A., et al.
Publicado: (2016)

Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD)
por: Ziedan, Ahmed, et al.
Publicado: (2019)

Impact of Intravenous Iron on Oxidative Stress and Mitochondrial Function in Experimental Chronic Kidney Disease
por: Nuhu, Faisal, et al.
Publicado: (2019)

A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysis-dependent chronic kidney disease patients with anaemia
por: Kalra, Philip A., et al.
Publicado: (2016)

High-dose intravenous iron reduces myocardial infarction in patients on haemodialysis
por: Petrie, Mark C, et al.
Publicado: (2021)

Intravenous Irons: From Basic Science to Clinical Practice
por: Bhandari, Sunil, et al.
Publicado: (2018)

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

Association between serum iron markers, iron supplementation and cardiovascular morbidity in pre-dialysis chronic kidney disease
por: Hasegawa, Takeshi, et al.
Publicado: (2023)

Factors Governing the Erythropoietic Response to Intravenous Iron Infusion in Patients with Chronic Kidney Disease: A Retrospective Cohort Study
por: Chukwu, Chukwuma A., et al.
Publicado: (2023)

A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients
por: Qunibi, Wajeh Y., et al.
Publicado: (2011)

Update of a comparative analysis of cost minimization following the introduction of newly available intravenous iron therapies in hospital practice
por: Bhandari, Sunil
Publicado: (2011)

Colorectal Cancer Presenting as Single Pulmonary Hilar Lymph Node Metastasis
por: Habib, Ahmed M., et al.
Publicado: (2018)

Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA
por: Dahl, Naomi V, et al.
Publicado: (2017)

Comparison of intravenous low molecular weight iron dextran and intravenous iron sucrose for the correction of anaemia in pre-dialysis chronic kidney disease patients: a randomized single-centre study in Nigeria
por: Waziri, Bala, et al.
Publicado: (2016)

Oral and intravenous iron treatment alter the gut microbiome differentially in dialysis patients
por: Liu, Huan, et al.
Publicado: (2022)

Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations
por: Koch, Todd A., et al.
Publicado: (2015)

The FIND-CKD study—a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale
por: Macdougall, Iain C., et al.
Publicado: (2014)

Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds
por: Toblli, Jorge E, et al.
Publicado: (2017)

Clustering phosphate and iron-related markers and prognosis in dialysis patients
por: Morooka, Hikaru, et al.
Publicado: (2021)

Thresholds of iron markers for iron deficiency erythropoiesis—finding of the Japanese nationwide dialysis registry
por: Hamano, Takayuki, et al.
Publicado: (2015)

Switching Patients with Non-Dialysis Chronic Kidney Disease from Oral Iron to Intravenous Ferric Carboxymaltose: Effects on Erythropoiesis-Stimulating Agent Requirements, Costs, Hemoglobin and Iron Status
por: Toblli, Jorge Eduardo, et al.
Publicado: (2015)

Iron status, inflammation and hepcidin in ESRD patients: The confounding role of intravenous iron therapy
por: Jairam, A., et al.
Publicado: (2010)

Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation
por: Lofruthe, Niklas, et al.
Publicado: (2016)

Oral and Intravenous Amoxicillin Dosing Recommendations in Neonates: A Pooled Population Pharmacokinetic Study
por: Keij, Fleur M, et al.
Publicado: (2023)

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2021)

POS-524 MORTALITY AMONG NEW HAEMODIALYSIS PATIENTS IN THE FIRST SIX MONTHS OF COVID-19 PANDEMIC
por: HAZARA, A., et al.
Publicado: (2021)

Safety of Intravenous Iron in CKD Stage 3-5 Patients Not on Dialysis: A Retrospective Cohort Study
por: AlSahow, Ali, et al.
Publicado: (2022)

A multicentre prospective double blinded randomised controlled trial of intravenous iron (ferric Derisomaltose (FDI)) in Iron deficient but not anaemic patients with chronic kidney disease on functional status
por: Bhandari, S., et al.
Publicado: (2021)

Intravenous iron supplementation in heart failure patients induces temporary endothelial dysfunction with release of endothelial microvesicles
por: Mause, Sebastian F., et al.
Publicado: (2023)

Increase of endocan, a new marker for inflammation and endothelial dysfunction, in acute kidney injury
por: Gunay, Murat, et al.
Publicado: (2018)

Retraction notice to “Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis.” Kidney Int Rep. 2021;6:613–623
por: Provenzano, Robert, et al.
Publicado: (2022)

Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk
por: Schaefer, Benedikt, et al.
Publicado: (2016)

Apixaban Dosing in Patients With Kidney Failure Treated With Peritoneal Dialysis
por: Lidgard, Benjamin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s8v7898448clmsq91rcam9utfe